ANDA 76405, held by Barr. Ethinyl Estradiol; Norethindrone Acetate.
As of Nov 16, 2026, ANDA 76405 (Tri-Legest 21), held by Barr, was first approved by FDA on Oct 26, 2007, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 26, 2007 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tri-Legest 210.02MG,0.03MG,0.035MG;1MG,1MG,1MG ยท tablet;oral-21 | Ethinyl Estradiol; Norethindrone Acetate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters